Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADAG Adagene	$2.39 +4.8%	$1.96	$1.33 ▼ $3.58	$112.59M	0.74	96,818 shs	193,346 shs
ANRO Alto Neuroscience	$3.91 +8.8%	$2.80	$1.60 ▼ $15.04	$97.21M	1.84	102,544 shs	157,542 shs
CYTH Cyclo Therapeutics	$0.72	$0.72	$0.55 ▼ $1.45	$23.72M	-0.57	585,177 shs	N/A
MGNX MacroGenics	$1.69 +17.4%	$1.50	$0.99 ▼ $5.10	$91.02M	1.65	523,921 shs	1.52 million shs

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADAG Adagene	+4.82%	+41.42%	+23.90%	+31.32%	-5.16%
ANRO Alto Neuroscience	+8.83%	+24.03%	+28.01%	+27.93%	-64.64%
CYTH Cyclo Therapeutics	0.00%	0.00%	0.00%	0.00%	-42.81%
MGNX MacroGenics	+17.36%	+6.96%	-6.63%	+11.92%	-53.06%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADAG Adagene	3.0157 of 5 stars	3.5	5.0	0.0	0.0	2.5	1.7	0.0
ANRO Alto Neuroscience	1.7202 of 5 stars	3.3	1.0	0.0	0.0	1.1	0.8	1.3
CYTH Cyclo Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
MGNX MacroGenics	4.3579 of 5 stars	3.3	3.0	0.0	4.4	2.4	4.2	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADAG Adagene	3.00	Buy	$7.00	192.89% Upside
ANRO Alto Neuroscience	2.57	Moderate Buy	$8.50	117.56% Upside
CYTH Cyclo Therapeutics	2.50	Moderate Buy	$0.95	31.83% Upside
MGNX MacroGenics	2.57	Moderate Buy	$3.60	113.02% Upside

Current Analyst Ratings Breakdown

Latest CYTH, MGNX, ANRO, and ADAG Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/18/2025	ANRO Alto Neuroscience	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
8/15/2025	ADAG Adagene	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$8.00 ➝ $7.00
8/15/2025	MGNX MacroGenics	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$8.00 ➝ $5.00
8/6/2025	ADAG Adagene	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
8/6/2025	ADAG Adagene	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$7.00
6/26/2025	ANRO Alto Neuroscience	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00

(Data available from 8/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADAG Adagene	$103.20K	1,090.97	N/A	N/A	$0.80 per share	2.99
ANRO Alto Neuroscience	N/A	N/A	N/A	N/A	$4.56 per share	N/A
CYTH Cyclo Therapeutics	$870.73K	27.24	N/A	N/A	$0.21 per share	3.43
MGNX MacroGenics	$149.96M	0.71	N/A	N/A	$0.74 per share	2.28

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADAG Adagene	-$33.42M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A
ANRO Alto Neuroscience	-$61.43M	-$2.39	N/A	N/A	N/A	N/A	-44.34%	-36.73%	11/11/2025 (Estimated)
CYTH Cyclo Therapeutics	-$20.06M	-$0.90	N/A	N/A	N/A	-2,847.19%	N/A	-307.16%	N/A
MGNX MacroGenics	-$66.97M	-$0.57	N/A	N/A	N/A	-21.99%	-40.24%	-14.62%	11/4/2025 (Estimated)

Latest CYTH, MGNX, ANRO, and ADAG Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/14/2025	Q2 2025	MGNX MacroGenics	-$0.59	-$0.57	+$0.02	-$0.57	$28.06 million	$22.24 million
8/13/2025	Q2 2025	ANRO Alto Neuroscience	-$0.57	-$0.65	-$0.08	-$0.65	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADAG Adagene	N/A	N/A	N/A	N/A	N/A
ANRO Alto Neuroscience	N/A	N/A	N/A	N/A	N/A
CYTH Cyclo Therapeutics	N/A	N/A	N/A	N/A	N/A
MGNX MacroGenics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADAG Adagene	0.01	2.29	2.30
ANRO Alto Neuroscience	0.18	18.43	18.43
CYTH Cyclo Therapeutics	N/A	0.17	0.16
MGNX MacroGenics	N/A	5.26	3.11

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADAG Adagene	9.51%
ANRO Alto Neuroscience	N/A
CYTH Cyclo Therapeutics	68.55%
MGNX MacroGenics	96.89%

Insider Ownership

Company	Insider Ownership
ADAG Adagene	21.20%
ANRO Alto Neuroscience	11.13%
CYTH Cyclo Therapeutics	29.78%
MGNX MacroGenics	13.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADAG Adagene	260	47.11 million	37.12 million	Not Optionable
ANRO Alto Neuroscience	N/A	27.08 million	24.06 million	N/A
CYTH Cyclo Therapeutics	9	32.92 million	23.12 million	No Data
MGNX MacroGenics	430	63.21 million	54.99 million	Optionable

CYTH, MGNX, ANRO, and ADAG Headlines

Recent News About These Companies

William Heiden Bought 909% More Shares In MacroGenics

5 hours ago | finance.yahoo.com

William Heiden Bought 909% More Shares In MacroGenics

5 hours ago | finance.yahoo.com

Stifel Nicolaus Keeps Their Hold Rating on MacroGenics (MGNX)

August 23 at 2:51 AM | theglobeandmail.com

MacroGenics (NASDAQ:MGNX) Director William Heiden Acquires 49,500 Shares

August 22 at 9:11 AM | insidertrades.com

MacroGenics, Inc. (NASDAQ:MGNX) Receives $3.60 Consensus PT from Analysts

August 21 at 2:17 AM | americanbankingnews.com

MacroGenics, Inc. (NASDAQ:MGNX) Receives Average Recommendation of "Moderate Buy" from Analysts

August 19, 2025 | marketbeat.com

MacroGenics (NASDAQ:MGNX) Given New $5.00 Price Target at Leerink Partners

August 18, 2025 | americanbankingnews.com

Comparing MacroGenics (NASDAQ:MGNX) & Prestige Consumer Healthcare (NYSE:PBH)

August 18, 2025 | americanbankingnews.com

Citizens JMP Keeps Their Hold Rating on MacroGenics (MGNX)

August 17, 2025 | theglobeandmail.com

MacroGenics (NASDAQ:MGNX) Posts Quarterly Earnings Results, Beats Estimates By $0.02 EPS

August 17, 2025 | marketbeat.com

Leerink Partners Lowers MacroGenics (NASDAQ:MGNX) Price Target to $5.00

August 17, 2025 | marketbeat.com

MacroGenics Reports Second Quarter 2025 Financial Results and Highlights Key Strategic Priorities

August 16, 2025 | uk.finance.yahoo.com

MacroGenics Revenue Doubles in Q2

August 16, 2025 | theglobeandmail.com

MacroGenics price target lowered to $5 from $8 at Leerink

August 16, 2025 | msn.com

MacroGenics (NASDAQ:MGNX) Stock Crosses Below Two Hundred Day Moving Average - Here's Why

August 15, 2025 | marketbeat.com

MacroGenics Inc. Reports Q2 2025 Financial Results

August 15, 2025 | msn.com

MacroGenics reports Q2 EPS (57c), consensus (38c)

August 14, 2025 | msn.com

MacroGenics (MGNX) Reports Q2 Loss, Tops Revenue Estimates

August 14, 2025 | zacks.com

MacroGenics: Q2 Earnings Snapshot

August 14, 2025 | timesunion.comT

MacroGenics Reports Second Quarter 2025 Financial Results and Highlights Key Strategic Priorities

August 14, 2025 | globenewswire.com

MacroGenics, Inc.: MacroGenics Appoints Eric Risser as President and Chief Executive Officer

August 14, 2025 | finanznachrichten.de

New MarketBeat Followers Over Time

Media Sentiment Over Time

CYTH, MGNX, ANRO, and ADAG Company Descriptions

Adagene NASDAQ:ADAG

$2.39 +0.11 (+4.82%)

Closing price 08/22/2025 03:57 PM Eastern

Extended Trading

$2.42 +0.02 (+1.05%)

As of 08/22/2025 06:54 PM Eastern

Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti- CD137 IgG4 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a masked fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase 1b/2 clinical development for the treatment of advanced/metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a v POWERbody, which is in preclinical stage for the treatment off-tumor toxicities, as well as develops anti-CD28 bispecific POWERbody TCEs. The company was incorporated in 2011 and is headquartered in Suzhou, China.

Alto Neuroscience NYSE:ANRO

$3.91 +0.32 (+8.83%)

Closing price 08/22/2025 03:59 PM Eastern

Extended Trading

$3.90 -0.01 (-0.18%)

As of 08/22/2025 06:35 PM Eastern

Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder. The company develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties which is in phase 2b clinical trial to treat patients with MDD; ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor which is in phase 1 clinical trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist which is in phase 1 clinical trial to treat patients with MDD and higher levels of anhedonia; and ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor which is in phase 1 clinical trial for the treatment of MDD. In addition, it develops novel pharmacodynamically synergistic combination and biomarker platform that collects patient-specific data to identify biomarker-characterized patient. The company was incorporated in 2019 and is headquartered in Los Altos, California.

Cyclo Therapeutics NASDAQ:CYTH

Cyclo Therapeutics, Inc., a clinical stage biotechnology company, engages in the development of cyclodextrin-based products for the treatment of neurodegenerative diseases. The company's lead drug candidate is Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug, which is in Phase III clinical trials for the treatment of Niemann-Pick Type C disease; and in Phase IIb clinical trials for the treatment of Alzheimer's disease. It also sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019. Cyclo Therapeutics, Inc. was incorporated in 1990 and is headquartered in Gainesville, Florida.

MacroGenics NASDAQ:MGNX

$1.69 +0.25 (+17.36%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$1.66 -0.03 (-1.78%)

As of 08/22/2025 07:59 PM Eastern

MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time